J&J's Erleada shows early wins in early prostate cancer but raises big questions for clinicians on June 01, 2026 Cessation of life early-stage Erleada apalutamide heart risk-benefit debate guidelines high-risk Localized locally advanced risk Malignant neoplasm of prostate Progression-Free Survival Stress Fractures +
Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline on April 30, 2026 Apellis acquisition assets Biogen early-stage growth strategy Immunology M&A Neurology speciality pipeline +
Roche's Oral SERD Giredestrant Shows Mixed Clinical Results but Remains Strategically Important on April 23, 2026 Clinical Trials early-stage lidERA Malignant neoplasm of breast oral SERD Roche (company) +
Breakout Ventures Closes $114M Fund III for AI-Driven Early-Stage Science and Biotech Startups on March 11, 2026 Breakout Ventures early-stage Fund III methionine seed investments +
Biopharma Bites: Breakout Ventures' $114M AI Fund, Amid Funding Shifts on March 11, 2026 AI biotech biopharma Breakout Ventures early-stage Funding Funds News [Publication Type] +
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus on January 13, 2026 Admilparant Burning Mouth Syndrome Camzyos Cobenfy early-stage JPM26 milvexian pipeline pumitamig +
Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends on October 13, 2025 assets Biopharma China early-stage Europe Licensing M&A Merus Metsera Physical activity Q3 therapeutic diversification U.S. Verona Pharma +
Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs on October 10, 2025 Ascenta Capital biotechs Clinical Trials early-stage Evan Rachlin Funds Investments multi-medicine platforms portfolio companies venture capital +
Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success on August 14, 2025 Biological Science Disciplines early-stage Hatteras Hatteras Opportunity Fund I Hatteras Venture Fund VII HistoSonics exit medtech Partner in relationship startups venture capital +
Frazier Life Sciences Raises $1.3 Billion Amid Biotech Downturn on August 01, 2025 biopharmaceutical startups early-stage Frazier Life Sciences Investments oversubscribed fund venture capital +
J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial on June 13, 2025 CAR-T therapy CD19 Antigens CD20 Antigens Clinical Trials dual-targeting early-stage Frequency of Responses J&J JNJ-4496 Lymphoma Phase 1b relapsed/refractory large-B-cell lymphoma +